<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00983554</url>
  </required_header>
  <id_info>
    <org_study_id>DK65038 (completed)</org_study_id>
    <nct_id>NCT00983554</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Steroids in Obese Men</brief_title>
  <official_title>Metabolic Effects of Testosterone Alone or in Combination With Dutasteride or Anastrazole in Obese Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be randomized into 4 study groups: 1. Placebo; 2. Anastrazole and Testosterone;
      3. Dutasteride and Testosterone; and 4. Testosterone only. A 2 step euglycemic clamp, body
      composition by dual X-ray absorptiometry scan, hormone and lipid assays will be performed to
      monitor metabolic effects of each treatment group. We hypothesize that increasing
      testosterone levels would increase lean mass, decrease fat mass and improve insulin
      sensitivity. We further hypothesize that improvements in the metabolic profile would decrease
      with anastrazole and improve with dutasteride, given in conjunction with T administration.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2005</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>body composition</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrazole and Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dutasteride and Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrazole</intervention_name>
    <description>Arimidex 1mg daily</description>
    <arm_group_label>Anastrazole and Testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Testim 10g daily</description>
    <arm_group_label>Anastrazole and Testosterone</arm_group_label>
    <arm_group_label>Dutasteride and Testosterone</arm_group_label>
    <arm_group_label>Testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>Avodart 2.5mg daily</description>
    <arm_group_label>Anastrazole and Testosterone</arm_group_label>
    <arm_group_label>Dutasteride and Testosterone</arm_group_label>
    <arm_group_label>Testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH antagonist</intervention_name>
    <description>Acyline 300 µg/kg subcutaneous injections every 2 weeks</description>
    <arm_group_label>Anastrazole and Testosterone</arm_group_label>
    <arm_group_label>Dutasteride and Testosterone</arm_group_label>
    <arm_group_label>Testosterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  free T level in the lower 25% of the normal range or below

          -  BMI ≥30kg/m2

          -  waist circumference ≥100cm

        Exclusion Criteria:

          -  pituitary tumors

          -  HIV infection

          -  Klinefelter's syndrome

          -  Kallman's syndrome

          -  uncontrolled hypertension

          -  diabetes

          -  congestive heart failure

          -  chronic lung disease

          -  acute coronary syndrome

          -  PSA &gt;4µg/L

          -  aspartate aminotransferase (AST)&gt; 3x upper limit of normal

          -  use of medications that might affect weight loss, muscle or bone metabolism or
             androgen metabolism, action or clearance.

          -  involvement in daily resistance training or high endurance exercise

          -  alcohol or drug dependence

          -  obstructive sleep apnea
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>51 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen L Herbst, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mårin P, Holmäng S, Gustafsson C, Jönsson L, Kvist H, Elander A, Eldh J, Sjöström L, Holm G, Björntorp P. Androgen treatment of abdominally obese men. Obes Res. 1993 Jul;1(4):245-51.</citation>
    <PMID>16350577</PMID>
  </reference>
  <reference>
    <citation>Mårin P, Holmäng S, Jönsson L, Sjöström L, Kvist H, Holm G, Lindstedt G, Björntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord. 1992 Dec;16(12):991-7.</citation>
    <PMID>1335979</PMID>
  </reference>
  <reference>
    <citation>DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214-23.</citation>
    <PMID>382871</PMID>
  </reference>
  <reference>
    <citation>Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006 Jun;154(6):899-906.</citation>
    <PMID>16728551</PMID>
  </reference>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2009</study_first_submitted>
  <study_first_submitted_qc>September 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2009</study_first_posted>
  <last_update_submitted>March 15, 2011</last_update_submitted>
  <last_update_submitted_qc>March 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Karen L. Herbst</name_title>
    <organization>University of California, San Diego</organization>
  </responsible_party>
  <keyword>testosterone</keyword>
  <keyword>insulin</keyword>
  <keyword>obesity</keyword>
  <keyword>aromatase</keyword>
  <keyword>5 alpha reductase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

